Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech
Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...
New Atlas5h
Next-gen weight-loss drugs will be here within 12 months
It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...
BioSpace20h
Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech
Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...
Novo adds to obesity drug pipeline via $200M deal with China-based biotech
The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...
Sesame, America’s Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly’s Obesity Medicine Zepbound
Streamlined access to authentic, FDA-approved, rigorously-tested Zepbound comes from Sesame’s direct integration with Gifthealth. Zepbound is the first and only FDA-approved dual glucagon-like peptide ...
Eli Lilly's weight loss drug Mounjaro launched in India; check prices, how it works
Eli Lilly launched its weight loss drug Mounjaro in India. According to the company, the injection is supposed to be taken ...
Onlymyhealth4d
Mounjaro Anti-Obesity Drug Launched By Eli Lilly In India, Check Benefits And Prices Here!
US pharma major Eli Lilly has launched in India its eagerly awaited diabetes and obesity drug Mounjaro tripeptide Read ahead ...
Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India. Prices here
Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...